This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Descriptive Study to Explore Certain Characteristics of Patients at Risk for Chronic Obstructive Pulmonary Disease (COPD) in a Primary Care Setting

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: November 13, 2009
Last updated: November 18, 2010
Last verified: November 2010
The purpose of this study is to explore if certain characteristics, easily detected within a regular primary care setting, may indicate that a patient at risk for COPD (45 ≤ age ≤ 80 years and a smoking history of ≥ 15 pack years) is prone to have a diagnosis of COPD according to Medical Products Agency guidelines.

Chronic Obstructive Pulmonary Disease

Study Type: Observational
Official Title: A Descriptive Study to Explore Certain Characteristics of Patients at Risk for COPD in a Primary Care Setting

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • The patients will test their lung function with a COPD-6 screener for COPD and compare with regular spirometry. Medical records will be checked for health care contacts with respiratory diagnosis during the last 24 months prior to the study visit. [ Time Frame: There will only be one visit in the study ]

Enrollment: 309
Study Start Date: October 2009
Study Completion Date: March 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
No treatment
Patients with a smoking history of 15 pack years or more.


Ages Eligible for Study:   45 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Primary care clinic

Inclusion Criteria:

  • Patients with a history of smoking one pack of cigarettes per day for 15 years or more

Exclusion Criteria:

  • Known Chronic Obstructive Pulmonary Disease
  • Known severe cardiovascular disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01013922

Research Site
Alingsas, Sweden
Research Site
Arvidsjaur, Sweden
Research Site
Askim, Sweden
Research Site
Atvidaberg, Sweden
Research Site
Bromma, Sweden
Research Site
Eslov, Sweden
Research Site
Falun, Sweden
Research Site
Gagnef, Sweden
Research Site
Goteborg, Sweden
Research Site
Hagfors, Sweden
Research Site
Helsingborg, Sweden
Research Site
Hisings Karra, Sweden
Research Site
Hollviken, Sweden
Research Site
Jarpen, Sweden
Research Site
Karlshamn, Sweden
Research Site
Karlskrona, Sweden
Research Site
Kil, Sweden
Research Site
Limhamn, Sweden
Research Site
Linkoping, Sweden
Research Site
Lulea, Sweden
Research Site
Stockholm, Sweden
Research Site
Timra, Sweden
Research Site
Varnamo, Sweden
Sponsors and Collaborators
Principal Investigator: Björn Tilling Åtvidabergs vårdcentral
Study Director: Georgios Stratelis AstraZeneca
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: MC MD, AstraZeneca Identifier: NCT01013922     History of Changes
Other Study ID Numbers: NIS-RSE-DUM-2008/1
Study First Received: November 13, 2009
Last Updated: November 18, 2010

Keywords provided by AstraZeneca:

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases processed this record on August 21, 2017